That is not the case. For facial vitiligo, treatment with a low dose can still achieve a repigmentation effect similar to that of the standard dose.
Excimer laser is a treatment that selectively delivers 308 nm ultraviolet light to vitiligo lesions, promoting the proliferation and migration of melanocytes.
Generally, mild erythema after treatment is considered an appropriate response, but it is not necessary to use strong energy that causes the skin to become red.
In a randomized controlled trial comparing low-dose and standard-dose treatment for patients with facial vitiligo, the repigmentation rates were 86.1% and 86.9%, respectively, showing little difference.
Furthermore, the proportion of patients who achieved 75% or more repigmentation was identical at 83.4% in both the low-dose and standard-dose groups.
In contrast, in the standard-dose group, 44.4% developed perilesional hyperpigmentation, and 22.2% experienced erythema or pain lasting more than 3 days, while no such side effects were observed in the low-dose group.
This means that for facial vitiligo, low-dose treatment is possible, maintaining efficacy while reducing erythema and hyperpigmentation.
